Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

July 30, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 51 min

Earnings Call Speaker Segments

Conor McNamara

executive
#1

Hi, everyone, and thanks for joining Illumina's Q2 2026 earnings call. We're here today to go over the financial results we published following the market's close, and we'll share some prepared comments before we open things up for your questions. You can find our earnings release in the investor relations portion of illumina.com. With me on the call are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob is going to kick things off with a business update on Illumina, and then Ankur will walk through the financials. Some of what we discuss will involve certain non-GAAP financial measures, and you can find a reconciliation to GAAP in today's release as well as in the supplementary data posted on our website. Except where noted otherwise, every growth rate we cite is on a year-over-year reported basis. Organic growth is adjusted for currency and acquisitions, and rest of world organic growth further leaves out Greater China because of our placement on China's unreliable entity list; this call is being recorded. A replay will be accessible on our website. It's our intent that all forward-looking statements made today will be protected under the Private Securities Litigation Reform Act of 1995. To better understand the risks and uncertainties that could cause actual results to differ, we point you to the documents Illumina files with the SEC, including our most recent Forms 10-Q and 10-K. With that, I'll hand the call over to Jacob.

Jacob Thaysen

executive
#2

Thanks, Conor. Good afternoon to all of you; the opening six months of 2026 were excellent for us, and Q2 gave us yet one more robust quarter. There is nothing that would make me more proud than what the Illumina team accomplished. Sales rose more quickly than at any point since my arrival at the company, propelled by mounting need for Illumina's technology as customers broaden their clinical uses. Our tight ties with top U.S. clinical buyers, plus a sizable installed base, bolster how lasting our standing is in these markets. Margins likewise landed above the guidance we gave even though costs ran higher than anticipated. I'd like to express gratitude to our teams for the attention and dedication they show our customers and shareholders. With these first half results, we sit in a solid spot going forward; for 2026 we are lifting our guidance on revenue growth and profitability, and we stay dedicated to hitting our long-range targets. Today, three topics will get my attention: how we performed during the quarter and the patterns emerging throughout our end markets, the ways we are growing our platform's value via new workflows and multi-omics abilities, and the headway we are making on our long-term strategy and financial targets. Let me begin with how the quarter unfolded. Organic revenue for the rest of world climbed 8.1%, surpassing the top end of our guidance, and three-plus years past launch, appetite for NovaSeq X stayed strong, with over 95 placements during the quarter. Alongside careful expense control, this produced margin and EPS that both beat guidance. Clinical markets, making up roughly 65% of sequencing consumables revenue, continued as our leading growth engine. Clinical growth in the rest of world was widespread across geographies and applications, showing notable strength in our U.S.-Canada region. Robust instrument placements across the last three quarters are boosting customer capacity and will fuel consumable growth for numerous quarters ahead. Placements will fluctuate quarter by quarter, yet demand stays elevated. In research and academic markets, results were better than in Q1. Customers are still wary as they work through funding uncertainty. We noticed a few hints of improvement toward the end of the quarter, but declaring a recovery now would be premature. These customers continue to be a key wellspring of innovation and help push clinical adoption as time goes on. Our growing multi-omics portfolio offers customers additional ways to examine biology and widens the means by which we can serve these markets down the road. Let me move now to innovation. Our strategy is to provide the best quality insights at the lowest end-to-end cost. The updates rolled out this quarter push that aim forward by widening what customers can accomplish on NovaSeq X and boosting the value of the Illumina ecosystem. In core sequencing, NovaSeq X stays at the heart of our approach. Customers put money into the platform not just for what it does today, but because they perceive a clear route to using it for years ahead. The roadmap we set out earlier this year gives them assurance that the X will keep supporting their workflows over time, which helps sustain demand for the platform. Not long ago, we introduced a whole genome MRD research workflow—a product built to assist customers in cutting down the time it takes to develop assets and in reducing what those development efforts cost. This solution operates on NovaSeq systems, and select customers now have early access to it. Past our core sequencing work, we're broadening what we offer in multi-omics, which aligns with the strategy we set out during 2024. During the summer, we grew our portfolio by bringing out the StrataMap Spatial, our spatial workflow that is sequencing-based. With this release, we extend what we can do in spatial biology and provide researchers with an additional route to examine tissue biology via the Illumina ecosystem. We're likewise witnessing ongoing momentum in proteomics after completing our purchase of SomaLogic. Our newly branded SomaScan and SomaSeq products are drawing considerable interest and assisting customers in linking proteomics with genomic insights; within BioInsight, we're growing our data and insights products to assist pharmaceutical customers in pushing forward AI-enabled drug discovery. BioInsight unites sequencing, perturbation tools, compute power, and AI in order to construct high-quality multi-omics data sets along with interpretation tools. Such capabilities can deepen comprehension of disease pathways, allow causality to be inferred, and make possible biological models that are more predictive. A leading early BioInsight undertaking is the Billion Cell Atlas, a genome-wide perturbation data set that deepens comprehension of disease biology and produces data for AI models. We're generating this data at a scale never seen before, with the quality and consistency required to back biological discovery. Having delivered more than 300 million cells so far, biopharma interest keeps expanding; we have begun booking revenue from our Billion Cell Atlas, and we brought in three additional partners after the quarter ended, which raises our total to six. Though it's still early, these milestones are a promising indication of the opportunity that lies ahead. Later in the year, we anticipate sharing further BioInsight updates as we broaden the ways customers can employ biological data to speed up discovery. Moving to our better 2026 outlook, we're lifting our full year revenue outlook to capture both our Q2 outperformance and what we expect for the rest of the year. The momentum we're observing, particularly from our clinical customers, leaves us more confident as we head into the second half. We now anticipate full-year rest-of-the-world organic revenue growth above 5%; we anticipate the rate of growth during the second half will stay broadly in line with the first half, even though the mix will change. Consumables revenue will keep growing off a larger installed base, whereas instrument growth eases against a tougher comparison after several quarters of elevated NovaSeq X placements. The growing NovaSeq X installed base will additionally contribute more consumables growth past 2026 and bolster our path toward high single-digit revenue growth in 2027. We're also lifting our EPS outlook, which captures Q2 outperformance, higher revenue expectations, and ongoing expense discipline. Ankur will give the details during his remarks. Our refreshed guidance strengthens our progress toward the long-term financial targets we set out in 2024, and we stay focused on reaching them. We compete in a healthy market that holds substantial untapped opportunity. We think that if we keep rolling out new technology that makes customers’ workflows better and gives them more capabilities, we’ll stay in the lead as the market changes; after 3 straight quarters of growth, we’re heading into the second half in a better spot. Our teams feel a lot of energy from how people have responded to the end-to-end workflows we launched not long ago. That enthusiasm shows we’re working on the right challenges and makes our innovation priorities even clearer. We’re also making the group that leads this effort stronger. Michael Sullivan and Julie Coletti joined our management team not long ago, bringing serious commercial and legal know-how as we grow the business. We’re just as happy to have David King and Dan Skowronski join our board. Their backgrounds in healthcare, diagnostics, and R&D will matter a lot as we push forward on our clinical and innovation priorities. I’d like to thank everyone on the Illumina team for their dedication and hard work, and our customers for believing in us. With that, I’ll pass it to Ankur, who will take us through the financial specifics before we go to Q&A.

Ankur Dhingra

executive
#3

Thanks, Jacob, and good afternoon to all of you. I'll take you through the financial results for our second quarter, give you some added detail on revenue, expenses, earnings, the balance sheet, and capital deployment, and then go over our revised outlook. But before diving into the specifics of the financial performance, let me offer a big-picture take on how the second quarter unfolded. In Q2, both our revenue and our earnings came in above what we had expected and guided. Organic revenue ex-China was up 8%, margins exceeded our expectations, and EPS came in at $1.31, which represents 10% growth year-over-year. We placed over 95 Xes. Now to the details. For Q2, Illumina brought in $1.16 billion in revenue. That's up 9.5% from the same period last year, or 6.5% on an organic basis, and if you combine the effects of currency plus acquired revenue, that contributed about three percentage points to the growth figure we reported. Outside the U.S., organic growth came in at 8.1%. Sequencing consumables generated $775 million, which was a 5% year-over-year gain, both as reported and on an organic rest of world basis. Most of the revenue increase came from high throughput volume, since our NovaSeq X installed base continues to grow and drives additional volume compared with a year ago. When it comes to clinical markets, sequencing consumables revenue was up 15% if you exclude China, and the U.S. Canada region continued to post growth above 20%. In the Europe, Middle East, and Latin America region, expansion came in at a slower pace, largely driven by near-term dynamics that continue to play out there. For the first half, growth reached roughly 17%, which represents a slight step up from the second half of 2025, reflecting ongoing uptake of diagnostics based on sequencing as well as applications that use sequencing more heavily. For clinical markets, we are lifting our growth forecast to the upper portion of the range we previously guided, and for the full year we now anticipate growth in the mid-teens. In research and applied markets, sequencing consumables declined 7% in the rest of the world, and trends so far this year remain in line with the outlook we held when entering the year. The patterns we observed during this period were positive, and they included a quarter-over-quarter revenue increase of 9%. That said, we believe it's still premature to predict when the end market will recover, and for research and applied consumables in 2026, our expectation remains a decline in the mid to high single digits. We made further headway this quarter in shifting customers to the NovaSeq X. By Q2, approximately 83% of volumes and 59% of revenue had transitioned onto that platform. Despite the transition dynamics that continue, sequencing consumables posted robust growth. Clinical volume is now about 78% on the X, and by the close of 2026, we continue to anticipate clinical volumes will hit 80%-85% conversion. Turning to sequencing activity: on the high-throughput and mid-throughput instruments we have connected, total gigabase output climbed over 30% again compared with a year earlier, and clinical expansion was considerably stronger than that. Revenue from sequencing instruments came to $125 million, a 31% increase year-over-year in Q2 on a reported basis and on a rest of world organic basis alike, fueled by greater sales of NovaSeq X and the MiSeq i100. The money we put into supply delivered a substantial payoff this quarter, enabling us to ship over 95 NovaSeq X instruments during Q2. Interest in that platform remains strong, especially among a number of our largest clinical accounts, where we secured multiple orders for capacity expansion spanning several units, among them some connected to the launch of new clinical trials. Beyond that, we placed more than 10 NovaSeq 6000 units, since certain customers intend to keep using that platform for years ahead. Sequencing service and other revenue reached $154 million, rising 14% on a reported basis and also 14% on a rest of world organic basis. As Jacob noted in his prepared remarks, our Billion Cell Atlas program is building momentum, which produced greater data revenue from biopharma customers. Microarrays and other revenue came to $105 million, climbing 21% reported and including SomaLogic revenue, which keeps tracking toward the high end of what we expected from that deal. Measured on a rest of world organic basis, microarrays and other revenue fell 4%. Now on to the rest of the P&L. Non-GAAP gross margin reached 68.2%, landing a bit above what we had anticipated, particularly considering the product mix given relatively high instrument sales during the quarter. We also took on greater freight and memory costs this quarter. Non-GAAP operating expenses totaled $530 million and include SomaLogic expenses. On top of that, deferred compensation accounted for roughly 60 basis points this quarter, which is EPS neutral thanks to an offset in other income. Non-GAAP operating margin for the quarter was 22.5%, exceeding our guidance, powered by higher volume as the team did a superb job absorbing greater inflationary effects. Below the line, non-GAAP net interest and other expense came to $8 million for the quarter. On a non-GAAP basis, our tax rate came in at 20.5%, while average diluted shares were about 153 million, a figure that reflects the buybacks we've been running. Add everything up, and non-GAAP EPS reached $1.31 per diluted share — roughly 10% higher than a year ago, or about 13% if you set aside the dilution from acquisitions. Now turning to cash flow, the balance sheet, and how we allocated capital this quarter. Cash provided by operations totaled $201 million for the quarter, which is below what we'd normally see, due to the timing of tax payments and higher inventory levels from locking in supply of critical components for the coming quarters. We spent $39 million on capital expenditures. That left us with $162 million in free cash flow. During the period, we repurchased 900,000 Illumina shares for about $122 million, paying an average of $129.07 apiece. As the quarter wrapped up, roughly $1.8 billion was still available through existing buyback programs, and our intention is to continue buying back stock when opportunities arise. We ended the quarter holding around $1.17 billion across cash equivalents and short-term investments, alongside $1.99 billion in total debt, giving us a leverage ratio near 1.6x gross debt relative to trailing 12-month EBITDA. Taking everything together, our second quarter and first half of 2026 were outstanding, allowing us to lift our guidance for the entire year and giving us greater confidence in how we are advancing toward our long-term objectives. Let's now discuss our full-year 2026 guidance. When it comes to revenue, we are lifting our guidance for organic growth in the rest of world to more than 5%, which is up from the 2%-4% range we gave before, and we're also raising reported revenue guidance by $50 million at the midpoint, bringing it to $4.60 billion-$4.64 billion. That captures both the Q2 beat and our stronger expectations for the back half of the year; in addition, we anticipate landing near the upper end of what we previously said about the sequencing of consumables and instruments. On rest of world organic sequencing consumables growth, our expectation now is mid-single-digit growth, which includes mid-teens growth in clinical along with mid to high single-digit declines in research. This is due in part to a small revenue gain from our stronger-than-expected performance on X placements over the past two quarters, though most of that gain is not expected to show up until 2027, because clinical customers typically require six to nine months at minimum before consumables pull-through settles at normalized levels. For sequencing instruments in the rest of world, organic growth is now expected to reach low single digits in 2026. Demand for NovaSeq X remains strong, and we expect unit placements to remain elevated through the second half of the year, with year-over-year growth rates moderating somewhat. We're keeping our operating margin outlook unchanged, in the range of 23.4% to 23.6%. With the revenue forecast for the full year now higher, the resulting diluted EPS outlook comes to $5.30 to $5.40. At the midpoint, that's $0.12 above what we previously guided, and it represents 11% growth versus last year at the midpoint, or 14% once you exclude acquisitions. Now for Q3 2026 guidance: we're looking for organic revenue growth in rest of world of about 4.5%, reported revenue between $1.14 billion and $1.16 billion, non-GAAP EPS of $1.33 to $1.38, and a non-GAAP operating margin of roughly 24%. That implies about 150 basis points of margin expansion sequentially, which comes from a richer consumable mix as well as greater savings from cost actions and better efficiency. The momentum we built in the first half, combined with a clinical installed base that's expanding quickly, puts us in a great position to keep growing consumables for many years ahead. We're placing more X instruments to keep up with rising volume demand, and as those recent placements start running, that should speed up consumable revenue growth. Beyond that, we're beginning to see revenue come in from our Billion Cell Atlas, plus mounting customer interest in our multiomics portfolio, and our view hasn't changed that new products will contribute one to two points of growth next year. Taking all of this together, we're steadily moving toward the financial targets we've set for 2027. To wrap up, I'd like to thank the Illumina team for staying focused and executing with discipline all quarter long. The beginning of 2026 has been very strong, and I feel a great deal of optimism about how far we've come in getting Illumina back on a path toward durable expansion in both revenue and earnings over the long run. We appreciate your participation in today's call. At this point, I'll hand things over to the operator so the line can be opened for questions.

Puneet Souda

analyst
#4

Regarding NovaSeq X placements during the back half of the year — considering the clinical expansion you're witnessing, it really seems like there's no cliff on the clinical side. You're moving right past it. As you mentioned, you're already sitting above 5% for this year's guidance. Why shouldn't we be thinking about something beyond the high single-digit revenue growth you previously described for 2027? Thank you.

Jacob Thaysen

executive
#5

Well, Puneet, I appreciate those remarks a great deal, and we are certainly quite happy with how we performed this quarter. Above all, I genuinely hold the belief — I'm firmly persuaded — that the expansion and momentum visible in the clinical market are going to persist for many years ahead. The higher placement levels we achieved during the first half of the year demonstrate that. As you're aware, once instruments get placed, we ultimately begin seeing consumables being used on them, and that will fuel ongoing growth. As we set out, I believe it was 18 months back, we described a framework of 50 to 60 placements each quarter, and clearly across the recent few quarters we've been operating above that level; that genuinely reflects what's taking place in the clinical arena at present. Although we do observe some fluctuations upward and downward from quarter to quarter, we continue to believe that the elevated pace will carry into the latter half of the year. We feel good about that. Naturally, there will be some ups and downs along the way. On the subject of the clinical cliff, I concur that it isn't a cliff — it's a wave, and we are surfing it, as you put it. We believe substantial momentum exists there. Yes, I think there's a solid opportunity to sustain that momentum. As for 2027 at this moment, I remain strongly committed to delivering the high single-digit growth. We'll keep concentrating on building an extremely strong value proposition for our customers, and then we'll see where that leads us.

Tycho Peterson

analyst
#6

Hi there, and thanks. I'd like to ask about a few items — specifically, the quarter-over-quarter deceleration in clinical consumables. A topic that keeps coming up in our conversations with investors is whether, as customers make the switch to X, you're earning above normal levels on consumables. After all, at some point the 6000s will be retired. How are you factoring in that possible drag once customers who are running both platforms side by side eventually stop doing so?

Jacob Thaysen

executive
#7

Yes, Tycho, I appreciate the question. Let me begin with your second point: we keep observing volume growth on X, and we still see a good number of 6000s actively in use to run the existing installed assets. In fact, this quarter some customers even bought a handful of 6000s so they could keep their operations going. Naturally, they will migrate to X down the road, but we don't view that as a — it's simply a normal element of the business. We witnessed that same transition starting from HiSeq, in a fundamental sense. Just a handful of quarters back, HiSeq was still part of what we offered. My view is that this won't be regarded as any real headwind for us. On the clinical side, the momentum remains elevated. As Ankur said, our confidence stays strong, and that's the reason we're lifting our guidance for clinical consumable growth to the mid-teens, an upgrade versus what we saw at the start of the year. When you dig into the specifics — from the 20% growth we posted in the prior quarter to 15% now — well, first off, that's still quite robust. The U.S. is still growing at a pace above 20%, and that momentum is genuinely powerful. There's been some back-and-forth, particularly in the Middle East and Latin America. Everyone is aware of what's happening in the Middle East, I believe, and near term at least, it's weighing on the growth rate. I won't read anything further into it, but the key takeaway is that mid-teens growth is solid, it's still above where we were when the year began, and it's still very much fueling high single-digit growth for us next year on the way to that.

Vijay Kumar

analyst
#8

Hey Jacob and Ankur. Thanks for fielding my question, and congratulations on a strong finish here. If I zoom out and look at how the quarter played out, could you take us through the cadence across those months? Did anything unusual show up? The reason I ask is that your outlook for Q3 — 4.5% for the rest of the world — has me wondering why that comes down from 8%. What makes 8% something you can't keep up? What's baked into your assumptions around AI-driven revenue, or could that become a larger story for the stock over the medium term? Thanks.

Jacob Thaysen

executive
#9

Yes, Vijay. Thanks again — we're really thrilled with the placements we're putting up at the moment, and we think that level is elevated too. This isn't a one-time thing. A lot of our clinical customers are making investments aimed at the future. They're expanding the installed base. They're preparing for the volume they can see coming through their funnel. We're watching that happen right now. There's somewhat of a comparison effect, in that during the first half of last year, the installed base — or instrument placements — looked somewhat different from what we saw in the second half. Momentum began building gradually in the second half, which explains why the instrument compares look somewhat different. Our expectation is that consumables stay robust, and in fact, we think that momentum keeps building and becomes the primary growth engine as we head into next year. That's the key reason behind it. Turning to AI — yes, we're really enthusiastic about our work with BioInsight. We've now supplied over 300 million single cell to our customers within the Cell Atlas. Three additional pharma partners have come on board, bringing us to six pharma partners total. Ultimately, what gets customers so excited is that this data can help — above all — generate insight, directly informing their drug discovery programs; beyond that, and this is really where the potential lies, it becomes the groundwork for robust AI models of a quality that will become predictable in the way you approach quality. This is something we're enthusiastic about; it's still early days. We're already generating money from day one on this, on both the top line and the bottom line. I believe there's a substantial opportunity ahead of us in that area over the coming period.

Michael Ryskin

analyst
#10

Hey, can you guys hear me?

Jacob Thaysen

executive
#11

Yes.

Ankur Dhingra

executive
#12

Yeah. Hey, Mike.

Jacob Thaysen

executive
#13

Hey, Mike.

Michael Ryskin

analyst
#14

Great, thanks. I'll go ahead with that. Okay, let me just ask a follow-up about how 3Q and 4Q will be paced across the remaining part of this year. The third quarter does show a somewhat surprising decline. And what matters even more is that 4Q is being guided a bit above what we had modeled. Are you expecting anything out of the ordinary when it comes to seasonality? Feel free to discuss any purchasing that happened during the quarter. Clearly, a large number of boxes have been placed by you. On last quarter's call, you mentioned the backlog. Whether any stocking occurred or anything along those lines. Related to that as well, I'm aware there's one additional week in the fourth quarter. Please remind us how that is affecting the revenue assumptions you have for 4Q. And regarding margins and EPS, we just want to be sure our modeling is right on those. Thank you.

Jacob Thaysen

executive
#15

Thank you, Mike. Once more, the main point I'd like to lead with is that the momentum built during the first half, in my view, points toward the opportunity that lies ahead of us. As I mentioned, our clinical customers are currently expanding their install base so they can truly be prepared for the growth they are experiencing. Rather than framing it as a decline, my view is that Q2 was quite strong. Q3 is consistently somewhat below Q4, and I consider that a typical phasing pattern for us. That doesn't concern me much. My sense is this is landing in line with what we anticipated. On the whole, I believe the underlying trend remains robust. Ankur, let's bring you in on this.

Ankur Dhingra

executive
#16

Appreciate that, Jacob. So Mike, when you look at how Q3 and Q4 are phased, just picture the normal seasonal pattern — Q4 tends to be our biggest quarter of the year, and we expect that to stay true. Then there's your other question, about the additional week. That's right, this year Q4 includes one extra week, and that's mostly going to show up in consumables. From that extra week, in terms of run rate days, you'd probably see around half a point of revenue contribution. That plays into how we're thinking. Now, on the comment about a slowdown — broadly speaking, from where we sit, the business is holding up quite well. Consumables growth has been the steady story all year long. Where things move around is almost entirely on the instrument placement side. We do expect that elevated pace of instrument placements to carry on into the back half of the year. And as you know, that elevated pace began in the back half of last year.

Dan Leonard

analyst
#17

Many thanks. Hey, Jacob. Hey, Ankur. I've got a follow-up about how fast clinical is expanding. Could you walk through how widespread that clinical growth is, especially since the U.S. was up more than 20? I believe you said your biggest clinical accounts were particularly strong on instruments. I'd like to get a sense of whether that strength is concentrated or broad. And separately, could you address whether those customers have changed their application mix at all across the last two quarters? Thanks.

Jacob Thaysen

executive
#18

Yes. Thank you, Dan. Let me frame this once more first. Taken as a whole in clinical, the chance that exists within the clinical arena, moving NGS into healthcare, is still ahead of us. I believe there's an enormous opening for it to truly become standard of care in healthcare across the coming timeframe. Broadly speaking, I'm quite enthusiastic about that, and I believe it will fuel momentum in that area across numerous quarters and numerous years ahead. What we're delivering remains broad-based. Naturally, there are certain ups and downs within that, when you examine it region by region, as you pointed out, the U.S. is still the primary engine behind this growth, while every other region, with the exception of China, keeps expanding quite well. From an applications standpoint, oncology is still out in front. Within oncology, we're now observing a move where MRD is beginning to generate momentum. Measured in dollars, therapy selection remains the larger piece. MRD is arriving, and afterward we'll see MSAT also begin to become a genuine driver of this growth. We aren't truly seeing that in the figures yet. Rare diseases plus screening, NIPT screening and similar areas, are still expanding quite well, with oncology leading the group at this moment. Once again, broad base, currently powered mostly by, and still led by, the U.S.

Subbu Nambi

analyst
#19

Hey, guys. Can you guys hear me?

Jacob Thaysen

executive
#20

Yes.

Ankur Dhingra

executive
#21

Hi, Subbu.

Subbu Nambi

analyst
#22

Hi, everyone. Strong results. I've got a few questions regarding memory cost. Pricing keeps climbing, and supply allocations remain tight. What's your view on how things play out in the second half, particularly given the higher full Q instrument placements, and looking ahead to 2027, especially as you bring in additional GPU-based compute for next-gen products? I have one more question after that.

Jacob Thaysen

executive
#23

Subbu, on the whole, as you've observed across the past 24 months, the folks at Illumina have genuinely accomplished a strong job of offsetting the challenges that stood before us, on the top line as well as, without question, our cost structure. That's been substantial during these recent years. Last year, I'd say, was a solid illustration, when we achieved a 200 basis point gain, even with conditions that were fairly flat. This team truly understands how to manage such challenges. Clearly, memory cost and freight costs have been a challenge we didn't expect at the magnitude that has materialized. I'm quite happy with the way the team keeps executing and discovering methods to offset this extra expense. Those expenses are genuine; naturally, we're passing along a portion of that increase to our customers, and we're also pursuing many initiatives around operational excellence as another way to offset it. I believe we're advancing on numerous fronts, which I think demonstrates the strength of the Illumina team, and I'm genuinely enthusiastic about how they're stepping up to resolve it. We feel good about that. We feel good that we have it under control. Naturally, some costs are now clearly visible to us and must be addressed, and we've shown we're capable of handling them, and we'll keep doing so. I believe you had a follow-up?

Ankur Dhingra

executive
#24

Yeah, Subbu, I'll just jump in with a few things here. Appreciate it, Jacob. So Subbu, the elevated memory expense shows up within our Q2 numbers. That figure works as a baseline run rate for you. A large portion of it has already landed in the gross margin we reported. Like I said during my prepared remarks, over the quarter we locked in extra inventory and supply to cover the coming several quarters, so we can handle — or at minimum reduce the risk from — any short-term shifts in memory pricing. Now onto the other half of what you asked, regarding how this carries over into GPUs and similar, plus new products. A distinctive strategic edge on our side, from a cost structure standpoint, is that GPUs aren't part of our instruments' design. A different architecture is what our instruments rely on, and it's considerably cheaper and more cost efficient compared to those GPU architectures. As I noted, we've been locking in supply across the next several quarters.

Subbu Nambi

analyst
#25

That's really useful. Thanks a lot, Ankur and Jacob. For my follow-up — you've just posted a few quarters of placements that beat expectations. I mean, we're four years into the instrument launch, and these are the instrument figures. That's certainly something worth stopping to consider. Did the market hold off at all because it wanted more competitive information? And on a related note, what portion of this comes from a funding environment that keeps getting better? Thanks very much.

Jacob Thaysen

executive
#26

Yes, Subbu, I believe it points to the opportunity once more. What I mean is the value proposition that we offer our customers. From the conversations we hold with them, they keep seeing that Illumina exists to help them succeed. The innovations we keep bringing to our X platform also demonstrate that this platform still has plenty of headroom; it's the one worth putting money into. I think it shows how we keep pushing innovation forward, and naturally, it also shows that this market is quite robust. That mix, in my view, is what's coming out on top at the moment.

Harrison

analyst
#27

Hi, this is Harrison filling in for Mason. Appreciate you taking our questions. Regarding NovaSeq X placements during this quarter, did the split between clinical and non-clinical shift at all compared with recent quarters? Can you update us on what research customers are telling you about when they'll order and how budgets are being released this quarter? Has anything in the underlying order pattern changed relative to last quarter, even if the headline figure stays roughly the same?

Jacob Thaysen

executive
#28

Yes, I'd say on the whole, naturally, we keep seeing most placements land in the clinical arena, and we anticipate that will remain the case. Despite a better climate in academic research, the clinical opportunity will stay the biggest one, and so we also anticipate the bulk of placements there; that being said, we did also place instruments in academic research. There's certainly opportunity in that area as well. Fundamentally, I mean, on the whole, if you'd like to provide-

Ankur Dhingra

executive
#29

Sure, I can speak broadly about the research side too. When it comes to how placements break down, the split remains roughly 70/30 — with 70% going to clinical and the rest still directed toward research. I'd also like to remind everyone that our business is highly international, and research activity is spread across the globe, not only within the U.S. As for trends in the research market this quarter, we noticed somewhat more activity overall toward the back half of the quarter, particularly around funding being released in the U.S., along with a pickup in requests, coding, and so on. That said, I'd reiterate what I mentioned in our prepared remarks: we aren't factoring in any significant uptick in either that market or our revenue from it for the remainder of the year. Directionally speaking, there was a bit of improvement during the latter portion of the quarter.

Kyle Mikson

analyst
#30

Hey, everyone. Appreciate you taking the questions. Strong quarter. During this call, you all discussed multi-omics types of solutions, if I'm not mistaken. I believe StrataMap got announced; all of these look quite promising. You've got single-cell proteomics, and so on. In what way do we monitor that moving forward? What signals tell us the approach is succeeding? Are you going to disclose that separately later on, perhaps in the coming year? How are you factoring in each of these offerings along with the revenue they bring, say, during Q4? Thank you.

Jacob Thaysen

executive
#31

Yes, Kyle. On the whole, our portfolio has us enthusiastic. Like we said during the strategy updates we gave back in 2024, and which are now unfolding, the approach we've taken is performing quite strongly. As we put it, look, back then, and even now, our attention is largely concentrated. Naturally, the largest opportunity involves shifting our customers and transitioning them onto the X platform and truly ensuring it turns into the platform of tomorrow. I'd say that's now been demonstrated. I'd say that momentum is something we're witnessing. Driving into multi-omics formed the second component of that approach. Our belief is that multi-omics owns the future. Clearly, genomics alongside DNA sequencing is going to remain the backbone for any biological insights, yet you require multiple layers, ranging from various omics, from the genome right up through the proteome, plus different approaches for examining it, from bulk to single cell, and into spatial as well. Illumina aims to deliver that for our customers, not merely as library preps or sequencing, but as end-to-end workflows addressing the challenges customers face. Then layer on top of that a software angle, so you can genuinely obtain insights spanning the various modalities. In my view, that represents what's ahead. That's where the strength lies and where we genuinely unlock biology's understanding. Which is why we've truly intensified our commitment there. What we stated back in 2024 as well was our expectation that growth would arrive in the later portion of the strategy period, coming into part of 2026 and 2027, when we'd begin seeing that contribute 1 to 2 points of extra growth and incremental growth. That's unfolding the way we anticipated; the excitement around StrataMap is huge. It only recently launched. The interest we're witnessing in it is considerably greater than what we'd projected for ourselves. I'd say that's a good sign for that platform. It isn't the sole one available. TruPath is generating considerable momentum. My view is it'll be a genuinely robust platform down the road; we could continue through the various platforms. Let me pause there and just say there's plenty of enthusiasm regarding multi-omics and what we're accomplishing with our applications and in serving our customers.

Ankur Dhingra

executive
#32

Sure. To give you some color there, Kyle, the bulk of multi-omics offerings such as Single Cell or TruPath and so on appear within our consumables revenue, since they fall under the consumables work stream; after that, the Billion Cell Atlas, or any other BioInsight revenue tied to it, will appear within our services; we'll continue discussing it the way we did this quarter regarding the revenue contribution coming from our Billion Cell Atlas.

Jack Meehan

analyst
#33

I had one more thing for Ankur, specifically about how margins will move across the year. You posted 22.4% this quarter, and it rises to 24% in the next one; that's a fairly solid increase. I'm curious how much of that comes from mix as opposed to possibly other drivers, and if it ties into that, anything you could offer regarding revenue expectations for consumables against NGS instruments in Q3 would be genuinely useful. Thank you.

Ankur Dhingra

executive
#34

Yeah, absolutely, Jack. That's a really good question. As we remember, right at the beginning of the year, we talked about this margin step-up occurring over the course of the year. Because of how tariffs stood and every cost action we'd implemented, we expected a stronger set of outcomes in the second half. That thesis has been unfolding. Looking at Q2, with 22.5% operating margin, I noted we had some deferred comp, which has an EPS neutral impact. Setting that aside, our operating margin in Q2 was roughly 23%. From there into Q3, that's a 100 basis point step-up. Part of this stems from a greater share of consumables; we also have multiple cost actions inside our gross margin mix that we expect to materialize across the Q3 period. In the same way, further cost actions are coming in Q4 too. We feel broadly positive about how the actions are paced. My expectation is that most of them would appear on the gross margin line.

Jaden

analyst
#35

Hello, I'm Jaden, filling in for Casey. I just have one question about the mid and low throughput instruments. Could you take us through the way low and mid throughput instruments did during the quarter? And then specifically regarding mid throughput, are customers being held back because of what's happening in the end market, and how should we view that moving forward for the remainder of the year? Thanks.

Jacob Thaysen

executive
#36

I'll begin by tackling that by, once more, framing it around the fact that we offer the industry's widest instrument portfolio, where the X is truly aimed at high throughput. That's really what I'd describe as production-style sequencing. Meanwhile, low and mid throughput are, to a significant degree, more project-oriented sequencing. Because of that, different sorts of drivers will influence this. Naturally, with high throughput, you're running operations, and that's genuinely generating revenue for those customers as well. But if it's project-based, the calculation involved may differ. Consequently, mid throughput in particular responds more to the macroeconomic backdrop, which we've observed for a considerable stretch of time now; we feel quite positive about mid throughput; we keep seeing solid placements in that area. I honestly believe that over the medium term we'll witness some momentum there too, helped by the investments we're making in that area as well. We're genuinely thrilled about that. Turning to low throughput, we launched the MiSeq i100 slightly over 1 year back. That's a highly exciting instrument, and we've had many placements of it. We carried on the momentum we began in the prior year. That's a market segment performing really well for us at present. It also sits in a price range where, once again, you reach a point where the majority of labs can manage the cost of the instruments and begin sequencing, and the value proposition is genuinely compelling for our customers. High-end and low throughput are extremely robust at the moment. Mid throughput is comparatively subdued owing to the macroeconomic backdrop.

Conor McNamara

executive
#37

We appreciate everyone being with us on this call. A recording of today's session can be found in the investor portion of our site. That wraps things up for us, and we hope to connect with you at future events.

Operator

operator
#38

That brings us to the end of today's call; we appreciate everyone for joining in. At this point you're free to hang up, and we hope the rest of your day goes wonderfully.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.